Final Countdown For Blockbuster Boston Scientific Deal
This article was originally published in The Gray Sheet
Executive Summary
European Commission (EC) antitrust regulators signed off, with some conditions, on Boston Scientific's acquisition of Guidant April 11, leaving U.S. clearance as the only remaining hurdle to closing the deal
You may also be interested in...
Boston Scientific gets preliminary FTC okay
Acquisition of ICD manufacturer Guidant moves closer to completion after Boston Scientific inked an agreement with Federal Trade Commission staff on April 5. The firm says the consent decree resolves all outstanding U.S. government antitrust issues but still requires final sign-off from FTC commissioners. On or around April 7, the firm will withdraw and re-file its antitrust notification with the agency, giving commissioners 30 days to review the details of the new agreement. Boston Scientific also is awaiting the completion of an antitrust review by the Eur-opean Commission, which will likely push final closing of the deal to mid-April (1"The Gray Sheet" April 3, 2006, p. 3)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.